The potential benefits of vonoprazan as helicobacter pylori infection therapy

Muhammad Miftahussurur, Boby Pratama Putra, Yoshio Yamaoka

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)


Helicobacter pylori infection is a severe global health problem that is closely associated with acid-related diseases and gastric malignancies. Eradicating H. pylori is strongly recommended for lowering peptic ulcer recurrence and preventing gastric cancer. The current approved H. pylori eradication regimen combines a proton pump inhibitor (PPI) with two antibiotics. Unfortunately, this regimen failed to meet expectations mostly due to antibiotic resistance and insufficient gastric acid suppression. Vonoprazan, a novel potassium-competitive acid blocker, showed promising results as a PPI replacement. Vonoprazan inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions and forming disulfide bonds with the cysteine molecule of H+/K+-ATPase. Vonoprazan has superior pharmacological characteristics over PPI, such as no requirement for acid activation, stability in acidic conditions, shorter optimum acid suppression period, and resistance to cytochrome P (CYP)2C19 polymorphism. Several comparative randomized controlled trials and meta-analyses revealed the superiority of vonoprazan in eradicating H. pylori, notably the resistant strains. The adverse effect caused by vonoprazan is long-term acid suppression that may induce elevated gastrin serum, hypochlorhydria, and malabsorption. All vonoprazan studies have only been conducted in Japan. Further studies outside Japan are necessary for universally conclusive results.

Original languageEnglish
Article number276
Pages (from-to)1-14
Number of pages14
Issue number10
Publication statusPublished - Oct 2020


  • Acid suppression agents
  • Helicobacter pylori
  • Potassium-competitive acid blocker
  • Proton pump inhibitor
  • Vonoprazan


Dive into the research topics of 'The potential benefits of vonoprazan as helicobacter pylori infection therapy'. Together they form a unique fingerprint.

Cite this